• risk of ATDH between genotype groups for genetic variants other than variants of the 2 3 8 NAT2, CYP, GSTM1 and GSTT1 genes (henceforth referred to as "other genetic We performed meta-analyses for all the above associations that were investigated by at 2 4 6 least two studies. For single-nucleotide polymorphisms (SNPs) investigated by one study 2 4 7 only, ORs comparing genotype groups were calculated and summarised in a table, together 2 4 8 with the pooled estimates from the meta-analyses. 95% confidence intervals (CIs) were 2 4 9 reported for all ORs. For SNPs where all studies presented data for each genotype group separately, we 2 5 1 performed two pairwise comparisons; heterozygous genotype versus homozygous wild-type, 2 5 2 and homozygous mutant-type versus homozygous wild-type. For SNPs where all studies 2 5 3 presented data for combined genotype groups, we performed one comparison of the 2 5 4 combined genotype groups. For SNPs where some studies presented data for each 2 5 5 genotype group separately, and some studies presented data for combined genotype 2 5 6 groups, we performed both pairwise comparisons (using data from studies that reported on 2 5 7 each genotype group separately), and a comparison of the combined genotype groups 2 5 8 (using data from all studies). All meta-analyses were performed using the metan package in Stata 14 (19), using the 2 6 1 random-effects model, as we expected to observe heterogeneity between studies due to 2 6 2 differences in study design, quality of methods, ethnic background of participants, and zero events were observed in one of the genotype groups, a continuity correction of 0.5 was 2 6 6 used. Data were excluded from the analysis if there were no patients in one of the genotype 2 6 7 groups in a comparison. The HuGENet HuGE Review Handbook recommends that meta-analyses of genetic 2 7 0 association studies are stratified by ethnicity, and that pooling of results should only be 2 7 1 performed if effect estimates for different ethnic groups appear sufficiently similar (17).
7 2
Information on participants' ethnicity was not commonly reported; however, in an attempt to 2 7 3 follow this recommendation, we stratified our analyses by the countries in which studies 2 7 4 were performed. cohorts of patients were identified. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for 2 8 3 systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097. Thirty-eight articles (29 distinct patient cohorts) investigated the association between 2 8 7 GSTM1/GSTT1 or other genetic variants and anti-TB drug-related toxicity. In this review, we 2 8 8 include data from 35 articles (22-56), which included 28 distinct patient cohorts. We did not 2 8 9 include data from two articles (57, 58) as the data presented were unclear and we were 2 9 0 unable to clarify the data with the authors. We did not include data from a third article (59) 2 9 1 because for the GSTM1/GSTT1 gene, we suspected that data were reported for the same 2 9 2 cohort of patients as that included in a more recent article by the same author (43). Data on 2 9 3 other genetic variants presented in this third excluded article were unclear and we were 2 9 4 unable to clarify the data with the authors. The characteristics of studies included in this 2 9 5 review are provided in Additional file 3. Choosing which genes and SNPs to genotype Twenty-four articles provided a rationale for the choice of genes and SNPs to be 3 0 0 investigated. Eleven articles (7, 22, 30, 43, 44, 46, 48, 50, (54) (55) (56) did not provide such 3 0 1 information; however, none of these articles limited their reporting to only statistically 3 0 2 1 3 significant associations. Consequently, there is no evidence to suggest that selective 3 0 3 reporting of genes and SNPs is an issue of concern for the included studies. The median sample size was 245 (interquartile range 163-346), meaning that most studies 3 0 7 are likely to be at risk of being underpowered (18). Only one article (40) reported the a priori 3 0 8 power to detect pre-specified effect sizes. Twenty-two articles employed a case-control design (7, 24, 25, 27, 29-38, 40, 44, 45, 48- 3 1 2 52), and 13 articles employed a prospective cohort design (22, 23, 26, 28, 41-43, 46, 47, 53- Only eight articles mentioned genotype quality control procedures (7, 25, 26, 29, 30, 48, 51, previously published for the same population, a simple way of highlighting problems with 3 2 3 genotyping. Only five (25, 29, 48, 51, 52) of the 22 articles describing case-control studies 3 2 4 mentioned that genotyping personnel were blinded to outcome status; blinding minimises the 3 2 5 risk of bias during the genotyping procedure (18). For most articles (21/35, 60%), the number of participants analysed matched the study 3 2 8 sample size; therefore, there were no missing genotype data. For the remaining 14 articles 3 2 9 (25, 26, 31, 34-37, 45, 49, 51-55) , only five articles (26, 45, 49, 53, 55) reported the extent of 3 3 0 missing data for all genes and SNPs analysed. None of these articles described checking 3 3 1 whether missing data were randomly distributed; therefore, 14 articles were at risk of bias 3 3 2 from non-random missing data (18). No articles mentioned undertaking tests for population stratification. One article reported that 3 3 6 only patients who had been settled in the area for a minimum of three generations were 3 3 7 eligible for inclusion in the study (46). This design ensured that all study patients were from a 3 3 8 non-diverse ethnic group. All other studies were at risk of confounding due to population Nineteen articles (7, 23, 25-27, 30, 31, 34-37, 42, 48, 51-56) Sixteen articles made a specific assumption regarding the underlying mode of inheritance 3 4 8 (22, 24, 27-29, 32, 33, 36, 38, 41, 44, 45, 47, 49, 54, 55) . Of these, only four provided a 3 4 9 rationale for this assumption (28, 44, 45, 54) ; for the remaining 12 articles, there is a risk of only three of these articles (25, 31, 51) adjusted these analyses for multiplicity of testing; 3 5 4 therefore, there is a risk of inflating the type I error rate in the other two articles. Choice and definition of outcomes
There was large variation in the definition of hepatotoxicity; a table detailing the range of Definitions of other toxicity outcomes reported are provided in Additional file 5. These 3 6 3 definitions were generally not sufficiently detailed. Five articles (25, 26, 30, 41, 49) did not provide justification for the choice of outcomes, but 3 6 6 the choice of outcomes was appropriate to address the main study aim as described in the 3 6 7 article introduction. The remaining articles all provided justification for the choice of Only five articles (26, 33, 34, 36, 38) mentioned assessing treatment adherence. It was not 3 7 2 necessary to adjust for adherence in the analyses of one article, as patients were reported to 3 7 3 have good treatment adherence (26), and the other four articles that assessed treatment 3 7 4 adherence all excluded patients who were reported to have poor adherence. Three articles 3 7 5 (24, 46, 56) reported that treatment was administered by directly observed therapy, short-3 7 6 course, so it was unnecessary to measure adherence. For GSTM1, patients with homozygous null genotype were significantly more likely to 3 8 9 experience hepatotoxicity than patients with heterozygous or homozygous present genotype 3 9 0 (OR=1.44, 95% CI 1.15, 1.82). Moderate heterogeneity was observed in this analysis 3 9 1 (I 2 =51.2%). This heterogeneity may be due to the variable genotype frequencies in different The results of the sensitivity analyses (two pairwise comparisons) for the GSTM1 gene are 3 9 6 provided in Additional file 6. As only one study reported on each genotype group separately 3 9 7 for the GSTM1 gene, no meta-analysis was performed. Instead, we calculated ORs and 3 9 8 corresponding 95% CIs for this study for each comparison. No significant differences were For GSTT1, there was no significant difference in the risk of hepatotoxicity between patients The sensitivity analyses (two pairwise comparisons) also showed no significant differences We produced a funnel plot for each of the primary analyses (Additional file 7). There was no 4 1 7 evidence to suggest that publication bias was an issue of concern. 4 1 8 4 1 9
Secondary analyses: Other genetic variants and hepatotoxicity
The included studies reported data for 27 other genes, and 83 SNPs. A summary of all data 4 2 1 for the association between other genetic variants and hepatotoxicity is provided in 4 2 2 Additional file 8. There were sufficient data to perform meta-analyses for 14 SNPs of six different genes. Forest plots showing the results of these meta-analyses are provided in Additional file 9. The findings from these meta-analyses are: • For four SNPs of the PXR gene (rs3814055, rs2461823, rs7643645, rs6785049), no 4 3 0 significant differences were observed for either pairwise comparison. as only one study identified patients with homozygous mutant-type genotype. For the analyses of the rs1045642 SNP of the ABCB1 gene, and the rs4149056 and for the rs1045642 SNP (61), for the rs4149056 SNP (also known as SLCO1B1 521T-C) (62) 4 5 8 and the rs4149014 SNP (63). One study (Costa, 2012) investigated the association between GSTM1/GSTT1 and adverse heterozygous genotype versus homozygous wild-type for either polymorphism. Our systematic review and meta-analysis has demonstrated that performing robust synthesis 4 9 0 of the evidence base for associations between genetic variants of GST and other genes and conducting our review, we carefully considered these challenges, stratifying meta-analyses 4 9 5 by genetic variants, the combination of different genotype groups and outcomes. We also 4 9 6 stratified further by the country in which the study was conducted as a proxy for ethnicity, 4 9 7 which was not widely reported. We found that for GSTM1, patients with homozygous null genotype were significantly more 5 0 0 likely to experience hepatotoxicity than patients with heterozygous or homozygous present 5 0 1 genotype. We also found that for GSTT1, there was no significant difference in the risk of findings of previously conducted meta-analyses, which all identified a significant association 5 0 5 between GSTM1 null genotype and hepatotoxicity, and no significant association between 5 0 6 GSTT1 null genotype and hepatotoxicity (4, (9) (10) (11) (12) . In particular, Cai et al. (4) and Tang et al. (12) reported very similar ORs for both the GSTM1 and GSTT1 genes to those reported in 5 0 8 the current review. We also identified that for the rs3814057 polymorphism of the PXR gene, both the 5 1 1 heterozygous and homozygous mutant-type genotype significantly increased hepatotoxicity 5 1 2 risk compared with the homozygous wild-type genotype. Several areas of concern with regard to the quality of the included studies were identified.
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Most studies were significantly smaller than typically required to provide sufficient power to 5 1 6 detect a genetic association (18); however, there was an almost universal lack of reporting of 5 1 7 a priori power calculations (only one study reported this in the current review), and therefore 5 1 8 readers would not be aware of the possibility of false-negative results. In addition, 77% of 5 1 9 studies did not report on steps taken to ensure correct genotype allocation, suggesting that 5 2 0 results should be interpreted with caution. None of the studies reported on whether the 5 2 1 distribution of missing data had been checked. Data that are missing in a non-random 5 2 2 fashion can introduce bias to a study. Furthermore, heterozygous genotypes are particularly 5 2 3 difficult to identify compared with homozygous genotypes missing genotype data are not 5 2 4 missing at random (18). Most of the studies (34/35 [97%]) were at risk of confounding from population stratification, 5 2 7 as they did not report on steps taken to ensure non-diverse patient ethnicity, or adjust for 5 2 8 population stratification. Furthermore, 40% of the included studies did not report on whether 5 2 9 HWE testing had been conducted; HWE testing can expose irregularities in genotype 5 3 0 frequencies that could be caused by genotyping errors, population stratification and other 5 3 1 problems (18). Nearly a third of studies (31%) did not justify their choice of mode of 5 3 2 inheritance and may therefore be at risk of selective reporting. Finally, 77% of studies did not 5 3 3 adjust for treatment adherence and therefore the proportion of variability explained by 5 3 4 genetic variants may be underestimated in these studies (18). Despite these concerns regarding quality, none of the studies were considered to be so poor 5 3 7 methodologically to be excluded from sensitivity analyses. The ethnicity of included participants was not reported widely in individual studies and this is 5 4 0 an important limitation of the review, as the distributions of GSTM1 and GSTT1 genotypes 5 4 1 vary considerably between different ethnic populations (64). As a proxy for ethnicity, we 5 4 2 stratified our meta-analyses by the study country, making the assumption that multiple 5 4 3 studies from a single country were likely to be relatively comparable in terms of the ethnicity 5 4 4 of the included patients. However, this approach is not ideal, as the population of any given 5 4 5 country is often ethnically diverse, and consequently, we are unable to make inferences 5 4 6 about the impact of ethnicity on the associations between genetic variants of GST and other 5 4 7 genes and anti-TB drug-related toxicity. Definitions of hepatotoxicity varied substantially among the included studies (22 different 5 5 0 definitions across 33 articles), introducing heterogeneity into the meta-analyses. Jorgensen pharmacogenetic studies of anti-TB drugs. In most of the studies, patients were treated with a combination of anti-TB drugs, meaning 5 5 9
that it is very difficult to link pharmacogenomic factors to specific drugs. It is possible that 5 6 0 some studies included patients with rifampicin-or pyrazinamide-induced hepatotoxicity, for An additional challenge was identifying distinct patient cohorts from the included articles. If 5 6 6 multiple articles report data for the same patient cohort, data for this patient cohort must only 5 6 7 be included in meta-analysis once, otherwise participants are "double-counted", and the 5 6 8 pooled effect will be overly biased toward these outcome data, and the assumption about independence between cohorts will also be violated. For two articles (43, 59), we contacted 5 7 0 study authors for clarification about patient cohort overlap but did not receive a response.
7 1
Therefore, data from the older article (59) were excluded from meta-analyses to which both 5 7 2 articles contributed data. If the two articles reported data for distinct patient cohorts, then 5 7 3 data has been lost by excluding one article. Furthermore, there is a possibility that there 5 7 4
were cases of patient cohort overlap that we did not identify; if this is the case, some patients 5 7 5 may be double-counted in the meta-analyses. Finally, there is a lack of evidence in our review from Africa (only one study was conducted 5 7 8
in Africa (55)). TB is endemic throughout the African continent and genotype frequencies of 5 7 9 the GSTM1 and GSTT1 genes vary considerably across the region (67); however, mapping 5 8 0 of pharmacogenomic polymorphisms is scant in African populations. Therefore, the evidence 5 8 1 gathered and synthesised in this review is not representative of the global population most 
